The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

OBJECTIVE: A 12-week study assessed the efficacy and safety of a new oral antidiabetic agent, imeglimin, as add-on therapy in type 2 diabetes patients inadequately controlled with metformin alone. RESEARCH DESIGN AND METHODS: A total of 156 patients were randomized 1:1 to receive imeglimin (1,500 mg...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Fouqueray, Pascale, Pirags, Valdis, Inzucchi, Silvio E., Bailey, Clifford J., Schernthaner, Guntram, Diamant, Michaela, Lebovitz, Harold E.
Формат: Artigo
Язык:Inglês
Опубликовано: American Diabetes Association 2013
Предметы:
Original Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3579350/
https://ncbi.nlm.nih.gov/pubmed/23160726
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc12-0453
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы